---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-230144"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T23:27:21.771762+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Seres completes VOWST sale to Nestlé for ~$175M gross; debt retired, runway to Q4 2025

## Summary
- Received ~$175M gross at close: $100M upfront, $60M prepaid milestone, $15M equity; net ~$155M after ~$20M settlement.
- Repaid $128M to Oaktree, terminating $110M term loan; debt fully retired.
- Expects $50M installment in Jan 2025, $25M in July 2025; up to $275M future milestones tied to VOWST sales.
- Focus shifts to SER-155 (promising Phase 1b allo-HSCT data), SER-147; headcount cut from ~200 to ~100.
- Cash runway extended into Q4 2025; plans to seek Breakthrough Therapy designation for SER-155.

## SEC filing metadata
- accession: 0001193125-24-230144
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524230144/0001193125-24-230144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524230144/d873729d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-230144
- JSON: https://secwatch.observer/filing/0001193125-24-230144.json
- Plain text: https://secwatch.observer/filing/0001193125-24-230144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.